As previously mentioned, choosing and managing therapy for patients with AML who harbor TP53 mutations or have complex karyotypes remains challenging (Abramowitz et al., 2017; Latif et al., 2021; Hassin and Oren, 2023). This evidence concerns the gene TP53 and acute myeloid leukemia.